A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study

BACKGROUND: Most patients with resectable locally advanced esophageal and gastroesophageal junction (GEJ) adenocarcinoma (AC) receive concurrent chemoradiation (CRT) followed by esophagectomy. The majority of patients do not achieve pathologic complete response (pCR) with neoadjuvant CRT, and the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamdani, Hirva, Schneider, Bryan, Perkins, Susan M., Burney, Heather N., Kasi, Pashtoon Murtaza, Abushahin, Laith I., Birdas, Thomas, Kesler, Kenneth, Watkins, Tracy M., Badve, Sunil S., Radovich, Milan, Jalal, Shadia I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484871/
https://www.ncbi.nlm.nih.gov/pubmed/34604072
http://dx.doi.org/10.3389/fonc.2021.736620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484871/
https://www.ncbi.nlm.nih.gov/pubmed/34604072
http://dx.doi.org/10.3389/fonc.2021.736620

Ejemplares similares